8-K: SS Innovations Reaffirms Q1 2025 Guidance, Highlights Strong Order Trends in Q2

SS Innovations International reiterates its first quarter 2025 guidance and reports a significant increase in orders for its SSi Mantra surgical robotic systems in April 2025.

Summary

• SS Innovations International, Inc. reaffirmed its guidance for the first quarter of 2025.
• The company installed 14 SSi Mantra surgical robotic systems during Q1 2025, bringing the total installed base to 78 as of March 31, 2025.
• Revenue for Q1 2025 is expected to be approximately $6.4 million, with a gross margin of around 45%.
• As of April 30, 2025, 80 SSi Mantra systems have been installed in 75 hospitals, and over 3800 surgeries have been performed using the system.
• Orders for the SSi Mantra system in April 2025 totaled 9, a 200% increase compared to 3 orders in April 2024.
• The company anticipates reporting its first quarter 2025 financial results around May 15, 2025.

Sentiment

Score: 8

Explanation: The document conveys a positive outlook with strong order growth and reaffirmed guidance, suggesting confidence in the company's performance and future prospects.

Positives

• The company is experiencing strong growth in SSi Mantra system orders, with a 200% increase in April 2025 compared to April 2024.
• The installed base of SSi Mantra systems continues to grow, reaching 78 by the end of Q1 2025 and 80 by April 30, 2025.
• The SSi Mantra system has been used in over 3800 surgeries, indicating increasing adoption and utilization.
• The company is maintaining a healthy gross margin of approximately 45% for Q1 2025.

Risks

• The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.
• Preliminary Q1 2025 results are unaudited and subject to change.

Future Outlook

The company believes it is well-positioned to maintain its growth trajectory and achieve new milestones throughout 2025.

Management Comments

• Dr. Sudhir Srivastava, Chairman and CEO, stated that the company remains very pleased with the growth trajectory of its business following the Nasdaq uplisting.

Industry Context

The announcement highlights the increasing adoption of robotic surgery and the growing demand for cost-effective surgical robotic solutions, positioning SS Innovations as a key player in the global market.

Comparison to Industry Standards

• Intuitive Surgical, the maker of the Da Vinci surgical robot, is the market leader, but SS Innovations is trying to compete by offering a more affordable system.
• Medtronic and Stryker are also major players in the surgical robotics market, but SS Innovations is focused on making robotic surgery more accessible globally.
• The number of surgeries performed (3800) is still relatively small compared to Intuitive Surgical, but the growth rate is promising.

Stakeholder Impact

• Shareholders can expect continued growth and potential value appreciation.
• Hospitals and surgeons will have access to more affordable robotic surgery options.
• Patients will benefit from the increased availability of robotic surgery.

Next Steps

• The company anticipates reporting first quarter 2025 financial results on or about May 15, 2025.

Key Dates

Keywords

SS Innovations, SSi Mantra, Surgical Robotics, Robotic Surgery, Order Trends, Guidance, Revenue, Gross Margin